In the production of the insect repellent active 3-(N-butyl-N-acetyl)amino propionic acid ethyl ester (IR3535, CAS 52304-36-6), β-alanine ethyl ester hydrochloride is converted to the free base before sequential N-functionalization in a two-stage batch sequence. The salt is charged to a 5000 L glass-lined reactor equipped with a pitched-blade turbine and pH probe, dissolved in demineralized water, and adjusted to pH 8.5–9.5 with aqueous sodium hydroxide at 1.0 mol equivalent relative to the hydrochloride salt. Residual water is separated by extraction with dichloromethane, and the first-stage acetylation is initiated with acetic anhydride at 1.05–1.15 mol equivalent while the internal temperature is held at 0–5 °C for 30–60 min; the lower temperature window prevents saponification of the ethyl ester to free β-alanine acid, which is the critical impurity tracked by HPLC-UV at 210 nm with a C18 column (150 mm × 4.6 mm, 5 µm). The process control limit for free β-alanine acid is ≤2.0% by HPLC-UV; excursions above pH 9.5 during neutralization elevate this impurity and increase downstream emulsion formation at the solvent boundary, requiring an additional static separator pass. The second-stage N-butylation uses n-butyl bromide at 1.1–1.3 mol equivalent and tetrabutylammonium bromide at 0.02–0.05 mol equivalent as a phase-transfer catalyst; mixing at 120–150 rpm and a jacket setpoint of 20–25 °C yields a residual N-acetyl intermediate below 0.5% by GC-FID. Compliance is governed by the EU Biocidal Products Regulation (EU) No 528/2012 and, for US placement, by the Environmental Protection Agency under FIFRA 40 CFR Part 152; the relevant REACH dossier under Regulation (EC) No 1907/2006 includes ready biodegradability data generated according to OECD Test No. 301B. Finished biocidal articles include pump sprays, lotions, aerosol cans, and impregnated wipes containing IR3535 at 10–20 wt%, depending on regional authorization and product type.

Why Is the Hydrochloride Salt Preferred Over the Free Base in Solution-Phase Peptide Coupling?

β-Alanine ethyl ester hydrochloride functions as a C-protected β-amino acid building block in solution-phase peptide synthesis, and its use as the salt rather than the neat free base reduces batch-to-batch variability caused by carbonate absorption during storage and transfer. The salt is neutralized in anhydrous dichloromethane with N,N-diisopropylethylamine at 2.0 mol equivalent relative to the salt; the first equivalent neutralizes HCl and the second maintains a non-nucleophilic basic environment. The neutralization is carried out at -10 to 0 °C in a 2000 L glass-lined reactor with bottom-discharge filter, because the exotherm from HCl neutralization can increase the reactor headspace temperature above 10 °C and accelerate ester hydrolysis. The carboxyl component, typically an N-Fmoc- or N-Boc-protected L-amino acid, is pre-activated with EDC hydrochloride and HOBt monohydrate at 1.05 mol equivalent each relative to the carboxyl species, then contacted with the free base to form the amide bond over 45–90 min. Water content after neutralization is controlled below 0.05% w/w by Karl Fischer titration; above this threshold the ester hydrolysis impurity typically exceeds 0.8% by HPLC. The protected dipeptide is extracted, washed with 0.5 M hydrochloric acid and brine, then concentrated and crystallized from ethyl acetate/n-heptane. Chiral purity is monitored with a Chiralpak IA column (250 mm × 4.6 mm, 5 µm) and an acceptance level of ≤0.5 area% for the undesired enantiomer. Pharmaceutical intermediate production is conducted under ICH Q7 and ICH Q11 requirements; when palladium-catalyzed deprotection is used, residual palladium is limited to ≤10 µg/g by ICP-MS under USP <232>, and residual dichloromethane and ethyl acetate are reported according to USP <467>. Terminal product types include protected β-alanyl dipeptide intermediates and β-amino acid containing active pharmaceutical ingredients for oral solid-dosage and parenteral formulations.

When the synthetic target is L-carnosine rather than a C-terminal ethyl ester, β-alanine ethyl ester hydrochloride is first subjected to controlled ester hydrolysis. In a 1000 L glass-lined vessel, the salt is dissolved in deionized water and treated with aqueous sodium hydroxide at 1.05–1.1 mol equivalent at 0–5 °C for 2–3 h; the low-temperature hydrolysis stream is monitored by inline refractive index as a continuous trend, and HPLC analysis at 210 nm is used to confirm that the starting material peak falls below 1.0%. The resulting β-alanine hydrochloride solution is adjusted to pH 6.8–7.2 and concentrated under vacuum below 50 °C to limit byproduct formation. Coupling with L-histidine is then carried out in aqueous dioxane using EDC hydrochloride at 1.1 mol equivalent and HOBt monohydrate at 1.0 mol equivalent relative to β-alanine; L-histidine is charged at 0.95–1.0 mol equivalent, and the pH is maintained at 7.5–8.0 with sodium bicarbonate. After 16–20 h, the crude L-carnosine is precipitated by pH adjustment to 5.5–6.0, filtered in a Nutsche filter, and recrystallized from aqueous ethanol. The nutraceutical-grade material is released under 21 CFR Part 111 cGMP, with residual solvents tested against USP <467>; the specification for dioxane is ≤380 µg/g under ICH Q3C Class 2 and ethanol ≤5000 µg/g under ICH Q3C Class 3. HPLC purity is set at ≥98.0% at 210 nm, and the L-histidine-related impurity is limited to ≤1.0%. Terminal product types include bulk L-carnosine powder for encapsulation, effervescent tablets, and ophthalmic N-acetylcarnosine derivatives where national pharmacopoeial monographs apply.

Ester Hydrolysis Controls Optical Purity in Cosmetic Peptide Batches

Topically applied β-alanyl dipeptides, primarily L-carnosine and N-acetylcarnosine, are manufactured from β-alanine ethyl ester hydrochloride through a route that shares the peptide coupling chemistry of nutraceutical synthesis but differs in hydrolysis and purification controls. After amide formation, the ethyl ester is cleaved with lithium hydroxide at 1.05–1.15 mol equivalent relative to the ester in tetrahydrofuran/water at 0–5 °C rather than with sodium hydroxide, because the lithium counterion gives a sharper pH endpoint and reduces Cα racemization at the histidine residue. Cosmetic-grade batches are purified by preparative reverse-phase HPLC using a C18 column and an acetonitrile/water gradient; fraction pooling requires ≥99.5% peptide purity by HPLC-UV at 220 nm, and the product is lyophilized at -40 °C for 48–72 h. Finished leave-on formulations contain the purified peptide at 0.1–2.0 wt% after pre-dissolution in a glycerin/water phase at 40 °C; published data for this specific configuration is limited, and formulators must re-qualify stability under the intended preservation system. Manufacturing compliance is governed by Regulation (EC) No 1223/2009 and by GMP under ISO 22716:2007; microbial quality is tested by enumeration of aerobic mesophilic bacteria according to ISO 21149:2017, and heavy metals are controlled at ≤20 µg/g by ICP-MS based on USP <232>. Terminal cosmetic product types include anti-glycation serums, eye creams, and barrier repair emulsions; no direct addition of the hydrochloride salt to cosmetic formulas is performed because residual chloride and ethyl ester are not permitted at measurable levels.

When Residual Solvent Limits Are Tightened for Preclinical Supplies

At the preclinical supply stage, β-alanine ethyl ester hydrochloride is used by contract research organizations to synthesize β-peptide libraries through solid-phase peptide synthesis, where the C-terminal ethyl ester is retained during resin cleavage to permit subsequent fragment elaboration. The salt is not pre-neutralized; instead, the free base is generated in situ on a 2-chlorotrityl chloride resin with DIPEA. Loading is controlled at 0.3–0.8 mmol/g resin, and Fmoc-protected amino acid couplings are performed with 3.0 mol equivalent Fmoc amino acid, 2.9 mol equivalent HBTU, and 6.0 mol equivalent DIPEA relative to free amine sites. On a 100 mmol-scale automated synthesizer, the cycle time per residue is 35–50 min; incomplete coupling is detected by a Kaiser test or by UV monitoring of the Fmoc deprotection signal at 301 nm. Final cleavage from the resin uses 1–5% trifluoroacetic acid in dichloromethane, which liberates the β-peptide while preserving the ethyl ester; harsher cleavage with 95% trifluoroacetic acid would hydrolyze the ester and complicate downstream fragment coupling. Compliance for research and preclinical materials is based on ISO 9001:2015 and, where the library is intended for regulatory toxicity studies, on OECD Good Laboratory Practice; this is not a full GMP release. Because the resulting compounds enter in vivo screening, residual palladium is controlled at ≤1 µg/g by ICP-MS and residual dichloromethane at ≤600 µg/g by headspace GC following ICH Q3C principles. Terminal products are lyophilized β-peptide libraries, purified peptidomimetic hits, and reference standards supplied in 96-well screening formats.